Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 20/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5549342 | 0.90 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL5549317 | 0.90 | P2RX7 (1.00) | P2RX7 | |
| Hydrochloric Acid SCHEMBL5553877 | 0.89 | P2RX7 (0.98) | P2RX7 | |
| Hydrochloric Acid SCHEMBL5549341 | 0.89 | P2RX7 (0.98) | P2RX7 | |
| SCHEMBL5553045 | 0.88 | P2RX7 (0.75) | P2RX7 | |
| SCHEMBL5549866 | 0.84 | P2RX7 (0.82) | P2RX7 | |
| SCHEMBL5549877 | 0.84 | P2RX7 (0.82) | P2RX7 | |
| Hydrochloric Acid SCHEMBL5553078 | 0.83 | P2RX7 (0.80) | P2RX7 | |
| Hydrochloric Acid SCHEMBL5549856 | 0.83 | P2RX7 (0.80) | P2RX7 | |
| SCHEMBL14497213 | 0.82 | P2RX7 (0.67) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7227038-B2 | Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them | ASTRAZENECA AB (SE) | 2007-06-05 | — | — | US | claimed |
| US-20060160904-A1 | Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them | ASTRAZENECA AB (SE) | 2006-07-20 | — | — | US | claimed |
| US-7227038-B2 | Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them | ASTRAZENECA AB (SE) | 2007-06-05 | — | — | US | disclosed |
| US-7227038-B2 | Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them | ASTRAZENECA AB (SE) | 2007-06-05 | — | — | US | disclosed |
| US-7227038-B2 | Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them | ASTRAZENECA AB (SE) | 2007-06-05 | — | — | US | disclosed |
| US-20060160904-A1 | Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them | ASTRAZENECA AB (SE) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160904-A1 | Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them | BACE1, ADORA1, ADRA1D | P2RX7 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.